跳至主要内容
临床试验/NCT02099435
NCT02099435已完成不适用

A Prospective Observational Cohort Study of Hemospray for Lower Gastrointestinal Hemorrhage (APPROACH LGI)

Cook Group Incorporated4 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2015年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
4
主要终点
Percentage of device related adverse events

研究概览

简要总结

This study is to evaluate the performance of Hemospray for the teatment of nonvariceal lower gastrointestinal bleeding.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient in which Hemospray is used to treat an endoscopically confirmed nonvariceal lower GI bleed requiring hemostasis

排除标准

  • Less than 19 years old
  • Unwilling or unable to sign and date the informed consent
  • Pregnant, lactating or planning to become pregnant within 30 days of the procedure
  • Contraindicated to undergo colonoscopy
  • Medical/Endoscopic Exclusion Criteria
  • Actual or suspected lower GI perforation or fistula
  • Bleeding originating from inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
  • Actual or suspected ischemic colitis or infectious colitis
  • Unable to visualize site of active bleeding (such as suspected diverticular bleed where source is unable to be identified)
  • Unable to treat active site of bleeding (e.g., bleeding site cannot be reached by the colonoscope)

结局指标

主要结局

Percentage of device related adverse events

时间窗: 30 days

次要结局

  • Percentage of hemostasis of lower GI bleeds originating from multiple sources(30 days)
  • Percentage of recurrent bleeding that occurs outside the blood vessel(30 days)
  • All cause mortality(30 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验